Malignant Pleural Mesothelioma Treatment Market to Reach US$ 649.83 Million by 2031, Driven by Immunotherapy Advancements and Rising Oncology R&D

According to DataM Intelligence, the Global Malignant Pleural Mesothelioma (MPM) Treatment Market reached US$ 387.73 million in 2023 and is expected to reach US$ 649.83 million by 2031, growing at a CAGR of 6.8% during the forecast period 2024-2031. Market growth is primarily driven by increasing adoption of immunotherapy, rising incidence of asbestos-related diseases, expanding clinical research activities, and improving access to advanced oncology treatments across developed and emerging markets.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/malignant-pleural-mesothelioma-treatment-market?jd

North America (Largest Region) - Key Industry Developments
✅ November 2025: U.S.-based cancer centers expanded adoption of first-line immunotherapy combinations for MPM, improving treatment accessibility and standard-of-care protocols.
✅ October 2025: Increased government and private funding supported mesothelioma research initiatives, particularly focused on novel immuno-oncology agents.
✅ September 2025: Pharmaceutical companies strengthened real-world evidence programs in North America to support expanded indications and reimbursement for advanced MPM therapies.

Asia-Pacific (Fastest Growing Region) - Key Industry Developments
✅ November 2025: Hospitals across Japan, China, and South Korea expanded access to immunotherapy-based treatment protocols for malignant pleural mesothelioma.
✅ October 2025: Regional clinical research organizations increased participation in global mesothelioma trials, accelerating drug development and regulatory approvals.
✅ September 2025: Governments in Asia-Pacific strengthened rare cancer treatment programs, supporting improved diagnosis and access to advanced therapies.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=malignant-pleural-mesothelioma-treatment-market
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis
-By Treatment Type: Immunotherapy Leads the Market
Immunotherapy accounted for approximately 54.4% of the global malignant pleural mesothelioma treatment market share, driven by strong clinical efficacy of immune checkpoint inhibitors such as nivolumab, ipilimumab, and pembrolizumab. Chemotherapy remains an essential component, particularly cisplatin and pemetrexed-based regimens, while surgery and tri-modality therapy continue to play a role in early-stage disease management.
-By Type: Epithelial Segment Dominates
The epithelial subtype represents the largest share due to better prognosis and higher treatment responsiveness compared to sarcomatous and biphasic forms.
-By Patient Type: Male Patients Account for Higher Demand
Male patients dominate the market, reflecting higher historical occupational asbestos exposure rates.

Regional Insights
North America holds the largest share of the malignant pleural mesothelioma treatment market, accounting for 42.3% in 2023, supported by strong healthcare systems, early diagnosis, and access to advanced oncology drugs. Asia-Pacific is the fastest-growing region, driven by improving cancer care infrastructure, rising awareness, and expanding availability of immunotherapy and targeted treatments. Europe continues to demonstrate steady growth through supportive regulatory frameworks and ongoing clinical research.

Growth Drivers:
1. Increasing Adoption of Immunotherapy: Checkpoint inhibitors are reshaping the MPM treatment paradigm.
2. Rising Incidence of Asbestos-Related Diseases: Legacy asbestos exposure continues to drive patient volumes.
3. Advancements in Oncology R&D: Innovation in combination therapies and personalized medicine supports growth.
4. Expanding Clinical Trial Activity: Rare cancer research initiatives accelerate treatment development.
5. Improved Healthcare Access in Emerging Markets: Expands treatment uptake across Asia-Pacific.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/malignant-pleural-mesothelioma-treatment-market?jd

Key Players:
The major players in the Malignant Pleural Mesothelioma Treatment Market include Eli Lilly and Company, Bristol-Myers Squibb Company, Accord Healthcare US, Merck & Co., Inc., Novartis AG, Pfizer Inc., MEDYRA PHARMACEUTICAL, Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals PLC, and AstraZeneca, among others.

Key Highlights (Top 5 Key Players):
1. Bristol-Myers Squibb Company leads the immunotherapy segment with checkpoint inhibitor combinations for MPM.
2. Merck & Co., Inc. drives innovation through pembrolizumab-based oncology research.
3. Eli Lilly and Company contributes with advanced oncology pipelines and combination therapy strategies.
4. AstraZeneca focuses on targeted and immuno-oncology approaches for thoracic cancers.
5. Novartis AG supports rare cancer treatment development through precision oncology initiatives.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply-Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.